Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
First-of-its-kind drug shows promise against prostate cancer: ScienceAlert
Health

First-of-its-kind drug shows promise against prostate cancer: ScienceAlert

Stephen Atcheler
By Stephen Atcheler
November 18, 2026 3 Min Read
Comments Off on First-of-its-kind drug shows promise against prostate cancer: ScienceAlert

For nearly a century, oncologists have treated advanced prostate cancer by depriving tumors of testosterone – their primary fuel.

But this cancer is tricky. It can mutate and learn to “feed” on different hormones.

Destroying tumor testosterone receptors could be a way around the problem.

An experimental drug that does just that has paved the way for a combined Phase I and Phase II clinical trial.

The oral medication is called bavdegalutamide (ARV-110) and it is taken daily.

It was tested in patients with the most advanced form of prostate cancer at three institutions: Massachusetts General Hospital, the Yale School of Medicine and Arvinas, the biotechnology company that developed the drug and funded the study.

The first phase of the trial was conducted to reveal a safe dosage, and the second phase put this dosage to the test in cancer patients with different mutations in their testosterone receptors.

Nearly 60 percent of participants whose tumors harbored the T878/H875 genetic mutations saw their prostate-specific antigens drop by at least half.

This is an encouraging sign because it suggests that the cancer is responding to treatment.

In comparison, only 3 to 4 percent of men with other genetic profiles experienced the same improvements.

The results, published in the Journal of Clinical Oncologysuggest that this new drug may hopefully suppress cancer activity, albeit among a small subset of patients.

“Bavdegalutamide destroys your own natural protein breakdown system and speeds up the androgen receptor process,” explains oncologist Daniel Petrylak of Yale University.

“The drug degrades testosterone receptors, which control the growth of prostate cancer.”

All participants in the clinical trial received the same experimental drug, meaning there was no traditional control group.

In total, 20 participants with the T878/H875 genetic mutations showed particularly good results.

It took an average of 11 months before their cancer worsened on examination or they died.

In comparison, in men with other genetic profiles, it took around 4 to 5 months.

This does not necessarily mean that this medication shrinks prostate tumors or that patients will live longer if they take these medications.

But these are positive signs.

“There was a decrease in prostate-specific androgens. We also saw regression of soft tissue damage and improvement in pain,” says Petrylak.

“These are the parameters that indicate a positive response.”

When prostate cancer spreads and stops responding to androgen deprivation therapy, it is called metastatic castration-resistant prostate cancer (mCRPC).

It is often associated with prostate-specific antigen (PSA) levels in the blood.

mCRPC is incurable and ultimately fatal, although certain treatments can slow its progression and prolong life.

Existing therapies suppress testosterone production or prevent it from binding to and activating receptors.

Although these therapies may show initial effectiveness, the authors of this recent trial write that “approximately 20 to 40 percent of patients do not respond to these treatments and almost all eventually develop resistance.”

A drug like bavdegalutamide could help fill an important gap.

It seems particularly effective against testosterone receptors carrying T878/H875 mutations.

But despite the good results, many participants in this clinical trial reported negative side effects, including nausea, fatigue, vomiting, and diarrhea.

As a result, Arvinas is prioritizing another prostate cancer drug called ARV-766 (luxdegalutamide), which uses a similar mechanism of receptor destruction but has fewer side effects.

A combined phase I/II clinical trial of this drug is currently underway and will be completed in May 2027.

The research was published in Journal of Clinical Oncology.

This article was fact-checked by Fiona MacDonald and edited by Fiona MacDonald. Although we are proud of our process, we are only human. If you spot an error, please let us know.

Gn Health

Views: 4
Stephen Atcheler
Author

Stephen Atcheler

**Stephen** is a staff journalist at **DailyVoxa**, specializing in business, finance, technology, artificial intelligence, and global markets. He is committed to delivering timely, accurate, and insightful reporting that helps readers understand the forces shaping the global economy and the rapidly evolving digital landscape.Drawing on in-depth research and credible sources, Stephen covers breaking developments, industry trends, and emerging innovations with a focus on clarity, balance, and factual accuracy. His reporting is designed to provide readers with reliable information, practical context, and thoughtful analysis without sensationalism.As a member of the DailyVoxa editorial team, Stephen follows the publication's Editorial Policy, Fact-Checking Policy, Corrections Policy, and Ethics Policy. Every article is carefully reviewed to ensure it meets the highest standards of journalistic integrity, transparency, and editorial independence.

Follow Me
Other Articles
OpenAI sued by California after admitting to 80 incidents of loss of control
Previous

OpenAI sued by California after admitting to 80 incidents of loss of control

Celebrities react to Robert Pattinson's Bond casting: Florence Pugh, Brad Pitt
Next

Celebrities react to Robert Pattinson’s Bond casting: Florence Pugh, Brad Pitt

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.